Pharma’s new ‘sensible pricing’ behind cancer drug approvals, says NICE
Experts discuss the implications of the new, reinvigorated Cancer Drugs Fund, for pharma and patients.
The world’s first national database of cancer treatment outcomes has been launched in England.
Assessing HCPs’ social media comments about the new approach to cancer drug funding.
Liver cancer treatment latest earmarked for removal from CDF
NICE approval secured against background of renewed controversy
More CDF legacy products likely to face same fate
Pharma must embrace the opportunity to shape the UK’s political agenda in its favour.